Literature DB >> 24490045

Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6.

Gayathri Nagaraj1, Yousef Zarbalian1, Karin Flora1, Benjamin R Tan1.   

Abstract

Small bowel adenocarcinoma is an uncommon gastrointestinal malignancy with limited data on effective chemotherapy in the adjuvant setting, as well as for advanced disease. We present a case report of a patient with recurrent duodenal adenocarcinoma after resection and adjuvant chemotherapy who experienced a complete response to bevacizumab with oxaliplatin and 5FU (FOLFOX) followed by bevacizumab/capecitabine maintenance therapy for 2 years. The patient continues to be disease-free 8 years after his recurrence. This case highlights the potential of vascular endothelial growth factor (VEGF) inhibitors to enhance chemotherapeutic regimens for advanced small bowel adenocarcinoma.

Entities:  

Keywords:  Small bowel adenocarcinoma; bevacizumab; capecitabine; oxaliplatin

Year:  2014        PMID： 24490045      PMCID： PMC3904032          DOI： 10.3978/j.issn.2078-6891.2013.038

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  15 in total

1.  The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995.

Authors:  J R Howe; L H Karnell; H R Menck; C Scott-Conner
Journal:  Cancer       Date:  1999-12-15       Impact factor: 6.860

2.  Bevacizumab-based therapy for advanced small bowel adenocarcinoma.

Authors:  H Tsang; T Yau; P L Khong; R J Epstein
Journal:  Gut       Date:  2008-11       Impact factor: 23.059

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.

Authors:  Michael K Gibson; Christina A Holcroft; Larry K Kvols; Daniel Haller
Journal:  Oncologist       Date:  2005-02

5.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.

Authors:  L F Brown; B Berse; R W Jackman; K Tognazzi; E J Manseau; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

6.  Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.

Authors:  Bouthaina S Dabaja; Dima Suki; Barbara Pro; Mark Bonnen; Jaffer Ajani
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.

Authors:  Karl Y Bilimoria; David J Bentrem; Jeffrey D Wayne; Clifford Y Ko; Charles L Bennett; Mark S Talamonti
Journal:  Ann Surg       Date:  2009-01       Impact factor: 12.969

9.  Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.

Authors:  Michael J Overman; Gauri R Varadhachary; Scott Kopetz; Rosni Adinin; E Lin; Jeffrey S Morris; Cathy Eng; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

10.  Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.

Authors:  M J Overman; J Pozadzides; S Kopetz; S Wen; J L Abbruzzese; R A Wolff; H Wang
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640
View more
  3 in total

1.  Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: A multicenter retrospective cohort study by the Osaka Gut Forum.

Authors:  Motohiro Hirao; Masato Komori; Tsutomu Nishida; Hideki Iijima; Shinjiro Yamaguchi; Ryu Ishihara; Yuichi Yasunaga; Ichizo Kobayashi; Osamu Kishida; Masahide Oshita; Hideki Hagiwara; Toshifumi Ito; Kunio Suzuki; Yoshito Hayashi; Takahiro Inoue; Masahiko Tsujii; Harumasa Yoshihara; Tetsuo Takehara
Journal:  Oncol Lett       Date:  2017-06-01       Impact factor: 2.967

Review 2.  Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: Case report and literature review.

Authors:  Rosa Falcone; Michela Roberto; Marco Filetti; Elisabetta Anselmi; Paolo Marchetti
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

3.  A case report of small bowel adenocarcinoma with liver metastases: genetic profiling and clinical management.

Authors:  Wael Abdullah Sultan Ali; Weixing Liu; Yuanyuan Xiao; Juemin Fang; Qing Xu
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.